Attorneys in our Health Care & Life Sciences Group counsel health care providers, insurers, biopharmaceutical and device companies, and other entities throughout the country with respect to their most sophisticated legal challenges.

We strive to provide outstanding value to our clients while maintaining the highest professional standards in our work. Our success in doing so is evidenced by our selection as counsel by some of the largest, most highly regarded health care organizations in the country, as well as by smaller clients striving to make or expand their place in the health care market.

Our attorneys are consistently recognized by Chambers USA: America's Leading Lawyers for Business and The Best Lawyers in America for their dedication, superior skills, and practical savvy. We are a sought-after partner to health care businesses of all types and welcome the unique challenges and relationships each partnership brings.

We serve clients operating across the health care industry, including:

  • Academic medical centers
  • Hospitals and health care systems
  • Health centers (including FQHCs)
  • Multi-provider networks (ACOs, CINs, IDSs, IPAs, PHOs)
  • Universities and schools of medicine
  • Health plans and managed care companies
  • Pharmaceutical, biotechnology, and medical device companies
  • Physician groups
  • Health care data analysis companies
  • Commercial IRBs
  • Professional associations and societies
  • Ambulatory surgery centers
  • Health information technology companies
  • Research institutes
  • Laboratories (clinical, research, and others)
  • Government agencies
  • Research funders
  • Contract research organizations and other research service providers
  • Organ procurement organizations

We also provide a full range of strategic, regulatory, and government enforcement and litigation legal services. For more information on these services, please see the service line pages listed below.

Firm Highlights

Publication/Podcast

Responsible Research During the COVID-19 Pandemic

News

Michael K. Fee to Lead Verrill’s Health Care and Life Sciences Defense Practice

(January 22, 2020) – Verrill is pleased to welcome Michael K. Fee to the firm’s Boston office as a Partner in its nationally recognized Health Care & Life Sciences Group and as the leader...

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

Publication/Podcast

Due to COVID-19, Federal Agencies Relax Requirements Regarding the Provision of Telehealth Services

In the past few days, in an effort to help keep Medicare beneficiaries healthy during the COVID-19 pandemic, key federal agencies within the U.S. Department of Health and Human Services (“HHS”) and the U.S...

Publication/Podcast

COVID-19 Expanded Access Template

We are aware that many companies and health care providers are working to expedite the transfer of investigational drugs that may be helpful in treating patients suffering from COVID-19. Although these expanded access arrangements...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

Publication/Podcast

COVID-19: FDA Clinical Trial Guidance

On March 18, 2020, the U.S. Food & Drug Administration (“FDA”) published guidance for clinical trial sponsors, investigators, and institutional review boards (“IRBs”) on conducting clinical trials in the midst of the COVID-19 pandemic...

Publication/Podcast

Updated FDA COVID-19 Guidance for Conduct of Clinical Trials

On March 27, 2020, the U.S. Food & Drug Administration (“FDA”) updated its prior guidance on the “ Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic ,” with an appendix adding a...

Matter

Common Rule

Guided multiple clients through the implementation of the revised HHS regulations (the "Common Rule"), including reviewing and revising policies and procedures, and assisting with institutional approaches to implementation.